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Around 2,600 courses of chemotherapy are given in Lothian, UK, 
each year, to people with a range of cancer types, at all stages 
of disease and with different treatment intent. Decision-making 
around chemotherapy and other systemic anticancer therapy 
(SACT) can be challenging, both for clinical teams as well as 
their patients and those close to them. This is particularly true 
in the palliative setting, where the cancer cannot be cured but 
where there still may be signiﬁ cant beneﬁ ts from oncological 
therapy. However, the risk of treatment-related morbidity and 
mortality is real1 and this should be understood by patients, 
their families and carers. 
It is known that patients do not always have a good grasp of 
the extent of their cancer and the implications of this for their 
future;2 one such example, often misunderstood, is the fact 
that chemotherapy given for advanced cancer will not offer 
cure.3 A further consideration, often also poorly understood, 
is that even where chemotherapy does extend life, a good 
quality of life for this additional time is not a given.4 Concerns 
about the potential for overtreatment in advanced cancer are 
not new.5 However, with the spotlight on shared decision-
making6,7 and in the knowledge that chemotherapy and other 
SACT can carry signiﬁ cant burden to patients and those close 
to them, understanding how people feel about the decision-
making process is of great interest.
The aim of this study was to explore how patients who had 
undergone palliative chemotherapy at the Edinburgh Cancer 
Centre (ECC), UK, felt, with hindsight, about their decision; 
in particular, to gauge levels of ‘decisional conﬂ ict’, deﬁ ned 
as ‘the state of uncertainty about the course of action to 
be taken when choice amongst competing actions involves 
risk, loss or challenge to personal life values’.8 High levels 
of decisional conflict are concerning, with uncertainty 
suggesting that the patient may not have felt conﬁ dent about 
the decision they made. 
Methods 
We based our questionnaire on the SURE test, a validated tool 
developed to identify decisional conﬂ ict at the time of decision-
making (Figure 1).9 The ﬁ rst four questions were adapted 
for retrospective use and related to how patients felt at the 
time about the decision-making process. A ﬁ fth question was 
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added, in order to explore how people felt having completed 
chemotherapy about the original decision. The ﬁ ve questions 
each had four possible responses, producing a maximum 
20-point score indicating strong decisional certainty, both at 
the time of the original decision and with hindsight.
Patients with lung or gynaecological cancers who had 
completed at least one course of palliative chemotherapy, 
which typically included several cycles (doses) of treatment, 
were identified by their clinical teams during routine 
visits to the ECC. Interviews took place opportunistically, 
either before or after consultations. Palliative intent is an 
overarching term for chemotherapy given when the goal is 
not cure, but instead is to improve symptoms and/or to 
extend life. Patients were asked if they would be willing to 
complete the questionnaire with a medical student, BG, 
following their clinic appointment. 
BG completed the questionnaire with patients in a private 
clinic area. If patients offered unprompted comments 
or qualifications, these were documented. Unprompted 
comments provided insights into experiences and reﬂ ections 
on the decision-making process, adding nuance to the 
numeric SURE test results. We did not capture this data 
verbatim or undertake formal analysis. However, key issues, 
statements or terms were noted.
We received approval for the study from NHS Lothian following 
review by the Clinical Lead for Quality Improvement in the 
ECC, and ethical approval from the University of St Andrews 
Teaching and Research Ethics Committee.
Results
A total of 29 patients completed the questionnaire with 
BG between during July 2017. Of these, 21 patients had 
lung cancer, of whom eight were female and 13 male. The 
remaining eight participants had ovarian cancer. A summary 
of questionnaire results are presented in Figure 2.
The decision to undergo chemotherapy
A total of 22 out of 29 (76%) patients reported having felt 
‘very sure’ at the time of the decision that chemotherapy 
was the best choice for them, with the remaining four out 
of 29 (14%) feeling ‘quite sure’ and three out of 29 (10%) 
feeling only ‘a little sure’. None reported having felt ‘not 
at all sure’. All eight patients with ovarian cancer reported 
having felt ‘very much sure’ that the decision was right 
for them.
Having undergone chemotherapy, and with the beneﬁ t of 
hindsight, 25 out of 29 (86%) patients remained ‘very much 
sure’ that their decision to have treatment had been the 
right one, three out of 29 (10%) were ‘quite sure’ about 
this and only one patient was ‘not at all sure’. However, 
unprompted comments from four patients revealed that the 
decision to undergo chemotherapy had not necessarily felt 
like a choice. 
Figure 1 Questionnaire, adapted 
from the SURE test
Figure 2 Questionnaire responses in five domains from 29 patients
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Didn’t see chemotherapy as a choice, rather a necessary evil
Did not view chemotherapy as a choice, rather felt it was 
the only option
Chemotherapy was not a choice, but something that had 
to be done
There was no real choice – not forced but channelled 
in to it
Clinician support and advice around the decision
A total of 24 out of 29 (83%) patients felt ‘very sure’ that 
they had received enough support and advice to make the 
decision. Three out of 29 (10%) reported feeling ‘quite sure’ 
about this and two patients remembered feeling only ‘a little 
sure’. None reported having felt ‘not at all’ sure. Unprompted 
comments reveal that some patients felt that they had not 
received the type of information that they needed.
Felt there could have been more emphasis on the 
practicalities of chemo
Would like to have been more informed about the 
mechanisms by which drugs work
Information was provided in multiple formats but too 
generalised to be helpful
Wasn’t fully aware of all side effects until second round 
of chemotherapy
Patient understanding risks and beneﬁ ts of treatment
There was more heterogeneity in the responses relating 
to patient understanding of the risks and benefits of 
chemotherapy. Twelve out of 29 (41%) were ‘very sure’ that 
they knew the beneﬁ ts and risks of having chemotherapy, 10 
out of 29 (35%) were ‘quite sure’, six out of 29 (21%) ‘a little 
sure’ and one patient was ‘not at all sure’. This patient had 
lung cancer and had expressed a low level of conﬁ dence in 
the decision to have chemotherapy at the time.
Fewer patients still reported having understood the risks and 
beneﬁ ts of treatment as they applied to their own situation. 
Only seven out of 29 (24%) patients were ‘very sure’ about 
which beneﬁ ts and risks mattered most to them, nine out of 
29 (31%) were ‘quite sure’, six out of 29 (21%) ‘a little sure’ 
and seven out of 29 (24%) were ‘not at all sure’. 
One patient seemed not to have grasped that chemotherapy 
was not being given with curative intent.
Didn’t feel the risks were relevant, because without chemo 
the risk of dying was so great
A different patient shared their optimism that the chemotherapy 
would provide meaningful beneﬁ t.
If it’s going to help you in the long run, do it
Discussion
The majority of people we surveyed felt conﬁ dent that the 
decision to undergo chemotherapy had been the right one, 
both at the time that they made the original decision and 
with hindsight. The vast majority also felt well supported 
and advised by their clinicians in relation to the decision. 
However, the patient sample included only: patients who had 
elected to receive chemotherapy; those who had completed 
their treatment and remained well enough to attend clinic; 
and, those considered by the clinician to be robust enough 
to invite to interview. Our relatively positive ﬁ ndings may be 
due to this selection bias, or could reﬂ ect genuine comfort 
in decision-making in Scottish oncology clinics. 
Patients reported less conﬁ dence in their understanding of 
speciﬁ c risks and beneﬁ ts of treatment, and less conﬁ dence 
still in how these risks and beneﬁ ts applied to their own 
situation. What we do not know is the extent to which patients 
were offered the opportunity to understand more about risks 
and beneﬁ ts, or to consider how these related to them as 
individuals. It is possible that patients chose to make their 
decision without this knowledge, but it is also possible that 
they did not; and that they would have made a different 
decision had they understood more.
Unprompted comments from patients revealed specific 
areas where patients’ information and support needs 
were perhaps less well met. One important area raised by 
patients’ comments was the extent to which chemotherapy 
was perceived as a choice. Four patients described having 
felt that there had been no choice. However, exploring the 
meaning behind their comments was beyond the scope of 
our study.
Clinicians cannot assume what a patient’s preference 
around cancer treatment might be and it is accepted that an 
exploration of preferences should be part of the oncology 
consultation.10 Shared decision-making, where people are 
empowered to be active partners in treatment choices, is a 
cornerstone of the Scottish Chief Medical Ofﬁ cer’s report, 
Realistic Medicine.6 In practice, patients attending oncology 
clinics to discuss the option of palliative chemotherapy may 
do so with an already established preference to undergo 
chemotherapy.11 Preconsultation preferences have been 
shown to strongly predict the likelihood of whether the person 
with cancer goes on to receive chemotherapy.12 Patients are 
inﬂ uenced by a range of people, including those close to 
them and their professionals, when making a decision about 
cancer treatment.13 In one study of women with advanced 
breast cancer, the oncologist was often the most inﬂ uential 
person in their decision; and in the majority of cases the 
oncologist had recommended treatment.14 The reality is that 
many patients defer to their clinicians when making decisions 
about treatment and this has implications for the shared 
decision-making and informed consent process. 
We do not know the speciﬁ cs of what had been discussed in 
clinic with patients in our study, since we saw them after they 
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had completed their treatment. One study in which oncology 
consultations around chemotherapy for advanced cancer 
were recorded revealed that oncologists commonly asked 
about patient preferences, and often early in the discussion.11 
However, this was often at the expense of exploring the values 
or knowledge that underpinned the expressed preference. 
A deliberative approach to consultation, where values 
and information are shared in a model that enables joint 
preference construction, was proposed; this is in line with the 
landmark Montgomery ruling relating to informed consent.15
A large North American survey of people with advanced cancer 
undergoing palliative chemotherapy revealed that a majority 
(69%) did not understand that their treatment would not offer 
them cure.16 The authors suggested that oncologists may 
be able to improve their patients’ understanding of realistic 
goals of treatment, but also cautioned that this could reduce 
patients’ satisfaction with their oncologist. This assertion 
is alarming, and may reﬂ ect a reality in the North American 
private healthcare system where patient satisfaction (even if 
based on false hope) may be viewed as preferable to honesty 
about uncomfortable truths. 
Another North American study interviewed people who 
had previously undergone palliative chemotherapy for 
advanced cancer.17 Patients varied in their reasons for taking 
chemotherapy, but also in the thresholds for potential survival 
beneﬁ t that were acceptable to them. Worryingly, some 
patients who had received chemotherapy would have made 
a different decision had they better understood the facts.
The concept of weighing up risks and beneﬁ t is very familiar 
to medical professionals, but it is something that patients 
and those close to them can grapple with. In our study, BG 
often needed to clarify what these terms meant. It is well 
recognised that patients commonly struggle with statistical 
information.13 One patient in our study expressed that they 
did not see risks as relevant to them as they felt that without 
chemotherapy their risk of dying was so great. In the palliative 
chemotherapy setting, the reality is that the risks of treatment 
typically equate to harm as a result of treatment, but as 
can be seen from this patient’s comment, ‘risk’ is open 
to misunderstanding. Perhaps the speciﬁ c wording of the 
SURE test regarding this area was too vague for the context; 
however, we expect that the added explanations offered by 
the researcher addressed this somewhat. The SURE test had 
previously been validated for use as a ‘real-time’ measure of 
decisional conﬂ ict. Our decision to adapt the questions for 
retrospective use may threaten the tool’s validity. In addition, 
we added a ﬁ fth question and summed the scores from all 
questions together. 
The lack of a robust real-world evidence relating to both the 
burden of cancer treatment but also the likely outcomes18 may 
limit the capacity for fully informed risk/beneﬁ t discussions. 
The American Society of Clinical Oncology and the European 
Society for Medical Oncology both draw attention to the 
potential burdens of cancer treatment to individuals and 
societies that extend beyond physical treatment toxicities; 
and provide practical guidance on how the value of cancer 
treatments might be assessed.19,20
A few patients in our study described that the decision to 
undergo chemotherapy had not felt like a choice. It might be 
that people knew that cancer treatment was right for them, 
with the sense of ‘nonchoice’ reﬂ ecting that. However, it could 
be that they were not aware of the alternative, or that the 
alternative did not appear favourable. 
There are several potential factors at play, any of which may 
contribute to the feeling that cancer treatment is the only 
option. We have strong societal narratives around battling/
fighting cancer,21 promoting the idea that ‘something 
must be done’. In this context, the option of not receiving 
cancer treatment may sit uncomfortably. However, the way 
in which the alternative to cancer treatment is understood 
and presented must be considered. In the UK and many 
other countries, ‘best supportive care’ is the term used to 
describe the plan when people are too unwell for, or choose 
not to have, cancer treatment. Whilst this sounds like a 
management plan that might offer something meaningful and 
helpful, our experience is that this is often not the case, for 
the most part because there is no agreement about what it 
means in practice.22 We suggest that unless we can describe 
what the best supportive care looks like in practical terms, 
the decision whether to undergo palliative cancer treatment 
will continue to feel like a nonchoice for many.
A culture within healthcare, where patients who choose 
not to undergo cancer treatment might be described as 
‘refusing’ treatment, is another factor to consider. A decision 
not to undergo cancer treatment has to be a legitimate 
option if the informed consent process is to be valid. Tessa 
Richards, an editor at the BMJ, highlighted the inadequacy of 
discussions about her own cancer treatment options.23 She 
describes her experience of living with incurable cancer, and 
her frustration that the option of not having further cancer 
treatment was not presented. The time and resource that 
goes into discussing treatment options for people at early 
stages of cancer is great, and arguably discussions around 
palliative cancer treatment and supportive care should be 
similarly available.24
Oncology consultations can be greatly pressured: taking a full 
clinical and social history; physical examination; explanation 
of the diagnosis/prognosis; discussion about risks and 
beneﬁ ts of potential treatment/s; and, informed consent if 
cancer treatment is the plan. Oncologists must also respond 
and adapt to the emotional reactions of patient and anyone 
accompanying them. Thus, we appreciate that the time for 
detailed discussions about risks and beneﬁ ts of treatment, 
as well as how these apply to the individual, is very limited.
It is recognised that patients may not describe regret in 
relation to chemotherapy until several months following its 
completion.25 Thus, for many patients in this small study, it 
may have been too early for them to experience this feeling 
or to report it. 
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Although we tried our best to ensure anonymity of patients’ 
responses, we are mindful that some patients may have 
exhibited response bias in terms of giving socially desirable 
answers, or leant towards acquiescence. 
In conclusion, participants reported high levels of conﬁ dence in 
their decision to undergo chemotherapy, despite simultaneously 
reporting lower levels of understanding of the risks and beneﬁ ts 
and how these were relevant to them. Perhaps patients having 
the opportunity to receive the information they want is more 
important than how much information they have chosen/been 
able to absorb. This approach is more patient-centred than a 
‘one-size’ model in which everyone is expected to understand 
the same level of information.
Further research with larger scale and robust studies 
would enable a deeper understanding of some of the more 
complex and nuanced areas highlighted by our ﬁ ndings. 
These include the factors that contribute to patients viewing 
the chemotherapy decision positively; the root causes 
and effects of the contrast between how much people 
understand and how conﬁ dent they are in their decision; 
and what leads some people to choose not to undergo 
palliative chemotherapy.
Decision-making around palliative chemotherapy for incurable 
cancer will always pose challenges. The onus is on clinicians 
to understand the information needs and preferences of the 
people they care for, and to strive to meet these needs in a 
personalised way. 
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